AEZS Aeterna Zentaris Inc.

0.5
-0.02  -3%
Previous Close 0.51
Open 0.52
Price To Book -5.51
Market Cap 11,642,494
Shares 20,031,610
Volume 105,232
Short Ratio
Av. Daily Volume 282,382
Stock charts supplied by TradingView

NewsSee all news

  1. AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

    – Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development discussions to secure a commercialization

  2. Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

    CHARLESTON, S.C., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), specialty biopharmaceutical company commercializing and developing therapeutics and

  3. Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

    – Study P01 is the first of two studies as agreed with the EMA in the Company's Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study P01 final study results expected in Q2

  4. Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

    CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical

  5. Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

    CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Zoptrex
Endometrial cancer

Latest News

  1. AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

    – Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development discussions to secure a commercialization

  2. Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

    CHARLESTON, S.C., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), specialty biopharmaceutical company commercializing and developing therapeutics and

  3. Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

    – Study P01 is the first of two studies as agreed with the EMA in the Company's Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study P01 final study results expected in Q2

  4. Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

    CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical

  5. Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

    CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective